Arena Shows Efficacy Against Pulmonary Hypertension

The trial enrolled 32 healthy volunteers in four cohorts of eight participants each. The drug showed dose-proportional pharmacokinetic exposure over the tested dose range.

San Diego-based Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, announced last week results from a Phase I clinical trial of an orally bioavailable agonist of the prostacyclin receptor, APD811, as a treatment for pulmonary arterial hypertension.

The randomised, double-blind and placebo-controlled trial enrolled 32 healthy volunteers in four cohorts of eight participants each. The drug showed dose-proportional pharmacokinetic exposure over the tested dose range.

Arena senior vice-president and chief medical officer William Shanahan said that the encouraging results of the study will make the company further evaluate the